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ABSTRACT
Human mesenchymal stem/stromal cells (hMSCs) have been shown to support 
breast cancer cell proliferation and metastasis, partly through their secretome. 
hMSCs have a remarkable ability to survive for long periods under stress,  and their 
secretome is tumor supportive. In this study, we have characterized the cargo of 
extracellular vesicular (EV) fraction (that is in the size range of 40-150nm) of serum 
deprived hMSCs  (SD-MSCs). Next Generation Sequencing assays were used to identify 
small RNA secreted in the EVs, which indicated presence of tumor supportive miRNA. 
Further assays demonstrated the role of miRNA-21 and 34a as tumor supportive 
miRNAs. Next, proteomic assays revealed the presence of ≈150 different proteins, 
most of which are known tumor supportive factors such as PDGFR-β, TIMP-1, and 
TIMP-2. Lipidomic assays verified presence of bioactive lipids such as sphingomyelin.  
Furthermore, metabolite assays identified the presence of lactic acid and glutamic 
acid in EVs. The co-injection xenograft assays using MCF-7 breast cancer cells 
demonstrated the tumor supportive function of these EVs. To our knowledge this is 
the first comprehensive -omics based study that characterized the complex cargo of 
extracellular vesicles secreted by hMSCs and their role in supporting breast cancers. 
INTRODUCTION
Human mesenchymal stem/stromal cells (hMSCs) 
are plastic adherent cells derived from bone marrow, 
referred commonly in the hematological literature as 
marrow stromal cells and later classified as multipotent 
mesenchymal stromal cells [1]. Various studies have 
shown that hMSCs act as stromal cells for solid tumors 
where they localize, integrate into the tumor associated 
stroma [2-5]. Once integrated, apart from providing 
stromal support, hMSCs promote tumor growth and 
angiogenesis [6, 7] through juxtacrine, paracrine and 
endocrine mechanisms [2, 8]. However the underlying 
mechanism by which hMSCs support tumor growth 
remains largely unexplored. 
Previously, our lab established an in vitro model 
system to study stromal cell survival under conditions that 
mimic the nutrient deprived core of solid tumors [9, 10]. 
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Serum deprived hMSCs (SD-MSCs) survive complete 
serum withdrawal using catabolic pathways such as 
autophagy, and they undergo specific epigenetic changes 
and secrete factors that support breast tumor survival and 
growth. Furthermore, we and others have shown that 
hMSCs secrete bioactive molecules such as IGF-1, VEGF, 
MMP proteins that act as paracrine mediators which either 
directly act on the target cells or stimulate the neighboring 
cells to secrete functionally active molecules that are 
known to inhibit apoptosis, enhance angiogenesis, and 
help in tissue regeneration [11-13]. In this study, we set 
out to complete the characterization of the extracellular 
vesicular (EV) fraction of SD-MSCs secretome.
Extracellular vesicles (EVs) are the secreted small 
membrane vesicles (30-200 nm) that form intracellular 
multivesicular compartments and that are released upon 
fusion of these compartments with the plasma membrane. 
The word “extracellular vesicle” is a generic term that 
refers to a series of membrane-bound organelles, which 
are commonly distinguished by their size range. More 
specific nomenclature for EVs includes exosomes (40-100 
nm diameter), microvesicles (50-1000 nm), and apoptotic 
bodies (50-5000 nm) [14]. However, there are no clear 
guidelines on terminologies or on different methods used 
for isolation and purification [15]. For the purposes of 
this study, extracellular vesicles (EVs) will be used for all 
organelles in this general category between 40-150 nm in 
diameter unless explicitly noted. We observed that their 
size varied based on cell type (Supplemental Figure S1) 
ranging between 100-200 nm and also varied based on 
the sizing technique used (Figure 1). For example when 
we tested EVs isolated using same technique but different 
sources, an osteosarcoma cell line (KHOS) and hMSCs, 
we have seen that the average size of purified fraction of 
secreted vesicles varied from 70-150 nm. Nanosight based 
analysis showed EVs in the sizes between 100-200 nm 
and electron microscopic assays demonstrated the ranges 
between 30-100 nm. To avoid inconsistency we have 
chosen to term the vesicles from SD-MSCs as extracellular 
vesicles (EVs), instead of exosomes. Various studies have 
also demonstrated a supportive role of EVs in cancer 
pathology, including the effects associated with cancer 
initiation, progression, angiogenesis, and metastasis [16-
18]. Although EVs are shown to be tumor supportive and 
involved in transfer of various content from host cell to the 
recipient, none of the above studies provided a complete 
characterization of the EV cargo. 
In this study, we isolated EVs from SD-MSCs and 
characterized their secreted cargo that includes small 
RNA, proteins, metabolites and lipids. A schematic for 
the data generation and analysis is presented in Figure 
S2. We found that hMSCs-derived EVs are cell protective 
by transporting supportive miRNAs and promote breast 
tumor growth in vivo. Our findings provide evidence on 
how hMSCs support breast tumor growth in a nutrient 
deprived tumor core by secretion of EVs and suggest 
that these EVs provide novel targets for therapeutic 
intervention. 
RESULTS
hMSCs Extracellular vesicles express CD81 and 
CD63
EVs were isolated from SD-MSCs through a series 
of ultracentrifugation steps of the conditioned media 
concentrate (as described in Materials and Methods), and 
the size of vesicles were analysed using NanoSight. While 
conditioned media contains heterogeneous population of 
vesicles ranging from 40-600 nm in size (Figure 1A), the 
purified fraction contained an enriched population of EVs 
with the mean diameter of 146 nm (Figure 1B). A series 
of experiments were performed to confirm the origins 
and morphology of the EVs. First, transmission electron 
microscopic (TEM) assays of serum deprived hMSCs 
showed the formation and secretion of microvesicular 
bodies that are released into the extracellular environment. 
TEM pictures of isolated EVs showed that the sizes varied 
from 30-100 nm (Figure 1C and 1D). Next, we used 
immunogold labelled antibodies to confirm the identity 
of EVs and found that purified EVs expressed specific 
markers for exosomes, CD81 and CD63 (Figure 1E, 1F 
and 1G). 
EV cargo includes anti-apoptotic proteins, 
bioactive lipids and metabolites
To identify and characterize the proteins, metabolites 
including lipids, and small molecules that may play roles 
in tumor cell protective function, we performed -omics 
based assays. The extracted peptides from EVs were 
analysed by LC-MS/MS for proteomics. Protein database 
searching and matching of the LC-MS data resulted 
in identifying a total of 281 proteins between the two 
donor hMSCs and both the donors shared 156 proteins. 
We compared the identified proteins with the ExoCarta 
database (exocarta.org) of exosomal proteins and observed 
that 35% of these shared proteins are found to be present 
within the top 25 of human originated exosomal/EVs 
proteins (data not shown). Furthermore, we classified 
the identified proteins using gene ontology (GO) based 
on biological process, molecular process and cellular 
function. The EV proteins are mainly involved in binding, 
rolling and intra/extravagination on cellular membrane 
(Table S1). Cellular components of the identified proteins 
revealed that the localisation of proteins is minimal in cell 
surface and inside nucleus (Table S1). 
Western blot assays confirmed the expression of 
PDGFR-β, LAMP2, TIMP-1, TIMP-2, CD90, CD9, 
and CD81 among other proteins detected in proteomics 
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analysis (Figure 2A). The relative expression of proteins in 
whole cells and EVs showed that LAMP2 and CD90 were 
enriched in EVs, whereas PDGFR-β is highly expressed 
in cells. Expression of CD9 and CD81, exosomal markers 
were expressed only in hMSCs derived extracellular 
vesicles. Additionally, the metallopeptidase inhibitors 
TIMP-1 and TIMP-2 were expressed only in EVs but not 
in cells.
Previous studies have shown that EV cargo is 
harboured with specific types of proteins, miRNAs, lipids, 
and mRNA [19, 20]. The lipid composition of extracellular 
vesicles is understudied and especially, lipidomics of EVs 
from hMSCs is not performed. For partial characterization 
of the lipid composition the isolated EVs were tested for 
the presence of - Sphingoid bases (sphingosine, dihydro-
sphingosine), Sphingoid base-1- phosphates (S1P, dhS1P), 
ceramide (Cn-Cers), dihydro-ceramide, alpha-hydroxy-
ceramide, diacyl-glycerol (DAGs), sphingomyelin (SM), 
dihydro-SM, hexosylceramide (glucosyl- and galactosyl-
ceramide), lactosyl-ceramide and ceramide  1- phosphate 
molecular species, separated glucosyl and galactosyl 
ceramide species. The data revealed high abundance of 
diacyl-glycerol and sphingomyelin, whereas dihydro 
ceramide and α-hydro ceramide were seen in trace 
amounts (Figure 2B).
Next for metabolomics assays to characterize the 
small molecule or metabolite composition in the EVs, we 
used CE-UV and HPLC-MS/MS studies. EVs sample (5 
μg protein) was lysed with methanol and the lysate was 
analyzed by CE-UV and HPLC-MS/MS. A typical CE-UV 
electropherogram obtained from the sample is shown in 
Figure 2C. Six peaks seen in the electropherogram indicate 
that they are small molecules (FW < ~500). The results 
indicate that small molecule compounds occur in EVs. 
The chromatograms obtained from HPLC-MS analysis the 
same sample are represented in Figure 2D. Since the levels 
of EVs compounds were very low, selected ion monitoring 
(SIM) chromatograms are shown. In the sample analyzed, 
Figure 1: Characterization of EVs isolated from hMSCs conditioned medium. (A) Particle size distribution in hMSCs 
conditioned media as determined by NanoSight and in (B) purified hMSCs EVs. (C) Transmission electron microphotographs of SD-
MSCs, - arrow indicates vesicles at the cell membrane surface. (D) Transmission electron microphotographs of purified EVs. (E) Immuno-
electron microscopy of EVs: negative IgG control. (F), CD81 detection, (G) CD63 detection. Bar represent 500 nm in C and 100 nm in 
D-G.
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lactic acid, glutamic acid, showed detectable levels of 
expression, while the levels of AMP, GSH, cystine, and 
cysteine were below the limits of detection of the present 
assay. 
hMSC-EVs cargo includes miRNA and lncRNA
Next the nucleic acid cargo of EVs was explored 
using next generation sequencing for small RNA. EVs 
isolated from two donors were subjected to sequencing 
as described in methods section. The data analysis to 
choose for microRNA and lncRNA with known role in 
cell cycle regulation was performed. A schematic for 
data analysis is shown in Supplemental Figure S3B. The 
data obtained from deep sequencing data analysis, two 
microRNAs and two lncRNAs were chosen. miR-21 and 
miR-34a from miRNA group and lncRNAs 7SK and Y1 
were chosen for further investigation to test our hypothesis 
that tumor supportive EVs includes a cargo that is anti-
apoptotic. miRNAs– 21 and 34a have been demonstrated 
to be involved in cell survival and proliferation [21-23]. 
To identify the expression levels of miR-21 and miR-34a, 
we performed real time PCR with total RNA isolated from 
hMSCs, SD-MSCs and EVs. The specificity of primers 
for these miRNAs was confirmed by dissociation curve 
(Supplemental Figure S4A). We found that miR-21 was 
expressed ≈25 fold in SD-MSCs and ≈2-3 fold in EVs 
when compared to hMSCs (Figure 3A). The expression 
of miR-34a was ≈20 fold in SD-MSCs and ≈3 fold in EVs 
(Figure 3B). Furthermore, we have tested the expression 
of human lnc-Y1 and lnc-7SK and observed an enrichment 
of 2-fold in EVs compared to hMSCs (Supplemental 
Figure S4B). These results suggest that stress induced by 
serum-deprivation resulted in upregulation of miRNAs 
and lncRNA involved in cell survival, thereby preventing 
Figure 2 : Detection of specific proteins and small molecule metabolites in EVs: (A) Western blot assays to confirm the 
presence of exosome/EV specific markers. (B) Relative and absolute abundance of lipid species in the EVs. (C) Electropherogram obtained 
from separating EV lysate by free zone capillary electrophoresis with UV detection, and (D) HPLC-MS detection of lactic acid and 
glutamic acid in the EV lysate. 
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the cells from apoptosis. Increased inclusion of protective 
miRNAs in EVs suggests the highly regulated miRNA 
processing to trigger and enable protective pathways in 
recipient cells. 
Inhibition of miRNAs- 21, and 34a induces cell 
death in SD-MSCs
 To investigate the specific and direct role of 
miR-21 and miR-34a in cell survival of SD-MSCs, we 
performed inhibitor studies using locked nucleic acids 
(LNAs) specific to the miRNAs. hMSCs transfected 
with LNAs for their respective miRNAs were grown 
either in complete conditioned media (CCM) or serum 
deprived media (SDM) and total RNA was isolated from 
transfected cells with LNA control or specific LNA were 
analysed by real time PCR. Efficient silencing of miRNA 
was observed in the transfected cells (Figure 3C, 3D). 
The amplified product of PCR was run on agarose gel to 
confirm the miRNAs silencing (Supplementary Figure 
S5A). Interestingly, in addition to SD-MSCs, inhibition 
of miRNAs 21 and 34a resulted in decreased survival of 
cells grown in CCM. Inhibition of miRNAs- 21 and 34a 
Figure 3: miR- 21 and miR- 34a are expressed in EVs. (A) Relative levels of miR-21 and (B) miR-34a in normal hMSCs, SD-
MSCs and SD-MSC EVs. Values were normalized to 5S RNA levels and subsequently to miRNA levels of hMSCs grown in complete 
conditioned media. The average of three replicates is displayed (*P < 0.05; ***P<0.001; n=3). Inhibition of miR-21 and miR-34a decreases 
cell survival. (C) Relative levels of miR-21 and (D) miR-34a in hMSCs (CCM) and SD-MSCs (SDM) after transfection with corresponding 
LNA inhibitors. Values are normalized to 5s RNA levels and subsequently to miRNA levels of hMSCs grown in complete conditioned 
media. The average of three replicates is displayed. (E, F) Celigo cell survival assays after treatment with LNA inhibitors (*P < 0.032; 
**P<0.012; n=3).
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resulted in decreased cell survival of hMSCs in SDM 
representing their importance in inducing protective 
pathways under stress conditions in the form of serum 
deprivation (Figure 3E, 3F, and S5B). Similar results 
were observed in hMSCs from different donors (data 
not shown). Taken together, EVs from hMSCs that carry 
miRNAs- 21 and 34a are protective in function for hMSCs 
under serum-deprived conditions.
EVs secreted by hMSCs increase survival of 
cancer cells under stress
 To study the role of EVs in cell survival, EVs 
derived from SD-MSCs were labelled with cell membrane 
marker PKH26 (red fluorescence) and incubated with 
breast cancer (MCF-7) or osteosarcoma (KHOS) cells for 
3 h and viewed under fluorescence microscope. The cells 
were scored for internalized EVs, and over 50% of tumor 
cells (Figure 4A), as shown by red fluorescence inside 
cells. Next, the functional anti-apoptotic fraction of the 
SD-MSCs group was quantified using a well-established 
model, where serum deprivation induces apoptosis in 
the cells [9]. MCF-7 and KHOS cell lines were grown 
in complete medium replaced with serum free media 
for 24 hr supplemented with EVs or not supplemented. 
Serum deprivation induced apoptosis in both MCF-7 
(Figure 4B) and KHOS (Figure 4C) cells, indicated by a 
significant decrease in the total number of surviving cells. 
However, in the presence of EVs over 15% increase in 
cell survival is observed. Specifically, MCF-7 exhibited 
better response to the presence of EVs (25%) compared to 
KHOS (15%) (Figure 4B, 4C). These results demonstrate 
Figure 4: hMSCs derived EVs are internalize by cancer cells and support cell survival. (A) MCF-7 breast cancer cells and 
KHOS osteosarcoma cells incubated with PKH26 labeled SD-MSCs derived EVs for 3 h. EVs have been internalized by cancer cells. Bar 
represents 100 µm. Insets shows the magnified image. (B) MCF-7 and (C) KHOS cells were cultured in either serum containing media or 
serum deprived media or serum deprived media supplemented with EVs. The cell survival is quantified by Cyquant DNA quantification 
method (*P < 0.05; **P<0.018; n=3).
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that extracellular vesicles derived from hMSCs exhibit 
anti-apoptotic function or cell protective function. 
EVs support breast tumor growth in vivo 
Cancer-derived EVs and exosomes in tumor 
environment influence cancer progression (reviewed 
in [24]). Next, we investigated the potential of 
hMSCs-derived EVs on the growth of breast tumors in 
immunodeficient mouse model. Equal numbers of MCF-
7 cells (1x106) were injected in mammary fat pads with 
matrigel in two groups of mice. One group received 
the cells alone and the other with 20 µg EVs from SD-
MSCs. Detectable masses of tumors were seen in both the 
groups from 2 weeks (Figure 5A). Larger tumors are seen 
in mice group, which received MCF-7 cells along with 
EVs when compared to mice received MCF-7 (Figure 
5A, 5B) cells alone. These results indicate that hMSCs 
derived EVs indeed support breast tumor growth in 
vivo. The hematoxylin and eosin staining of the tumors 
demonstrated that the tumors co-injected with EVs 
exhibited higher angiogenesis (Figure 5C).
Figure 5: EVs enhance breast tumor growth. (A) Xenograft assays of MCF-7 cells with or without EVs. The tumor sizes of 
MCF-7 + EVs were significantly higher than MCF-7 alone (*P < 0.05; **P<0.01; n=4). (B) Representative photos of tumors from each 
cohort orthotopically injected MCF-7 alone and MCF-7 and EVs, showing difference in tumor size (highlighted by dashed circles). (C) 
Hematoxylin and eosin stained sections showed tumors from MCF-7 + EVs have higher angiogenesis when compared to MCF-7 alone. (D) 
Schematic representation of hMSCs extracellular vesicles major components.
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DISCUSSION
Over the past several years, a significant amount of 
research has emerged documenting a role for hMSCs in 
accelerating tumor growth and metastasis [2, 24]. Given 
this complex interplay between hMSCs and tumor cells 
intercellular communication; the goal of this study was to 
assess the role of EV transfer from hMSCs to tumor cells. 
Several s rowth factors to enhance cancer cell growth [29, 
30], alters the cancer cell metabolism [31] and increase 
their tumorigenic ability [32]. Furthermore, CAFs increase 
the invasiveness of the cancer cells.
Previous findings from our laboratory [9, 10, 
33, 34] demonstrated that early passage hMSCs when 
subjected to serum deprivation selects an active and 
functional subpopulation of very early progenitor cells. 
These SD-MSCs remains undifferentiated but retains their 
differentiation potential into osteoblasts, chondrocytes, and 
adipocytes [10]. Furthermore, hMSCs utilize autophagy 
pathways to provide stromal support in a nutrient deprived 
and poorly vascularized core of solid tumors. In addition, 
experiments with hMSC secretome in tumor progression, 
demonstrated that epigenetic changes under stress direct 
expression of tumor supportive growth factors [9, 34, 
35]. Initial secretome characterization studies performed 
on SD-MSCs showed that they secrete tumor supportive 
factors such as VEGF-A, HGF, IGF-1 [35]. However 
those studies have not completely expounded on the 
molecular composition and mechanisms of the protective 
function of secretome. We have chosen to use SD-MSCs 
for studies related to EVs in tumor microenvironment 
because they offer several advantages: a) EV isolation 
and characterization will be true to the cell type as 
issues related to serum contamination are abrogated, b) 
the phenotype of SD-MSCs is closer to the stromal cell 
phenotype offering the functional advantage. 
The four known components that have a potential 
role in EV mediated cell-cell communication are small 
RNA, proteins, lipids and metabolites. We characterized 
important components of the EVs using comprehensive 
proteomic, genomic, lipidomic and metabolomics assays. 
This is the first report on complete biochemical and 
molecular characterization of EVs isolated from hMSCs.
It has become imperative to support the studies 
using EVs to include in-process data on their preparation 
because of the variability associated with various 
purification techniques [14]. Figure 1 demonstrates that 
ultracentrifugation purification assays have concentrated 
70-150 nm extracellular vesicles. The purified 
extracellular vesicles are double membrane and immuno-
electron-microscopic assays confirmed that EVs express 
CD81 and CD63, known exosome/microvesicle markers. 
A discrepancy is observed between two commonly 
used methods for EV size determination, Nanosight and 
electron microscopic assays; while the former identified 
the size to range between 100-200 nm, the electron 
microscopic images show particles between 30-100 nm. 
The inconsistency between techniques indicate a need for 
further investigation into developing a dependable assays 
for EV size determination. Based on the size determination 
and marker expression it is safe to assume that we are 
dealing with exosomes-type vesicles. However, we 
believe that defining a secretory vesicle based on size 
could be rather misleading especially in situations where 
the functional properties of the vesicles may be shared 
among various fractions of the secretome. Our primary 
goal of studying EVs to understand their biological roles, 
therefore we prefer to use the term EVs to define the 
secreted vesicles, which fall in the size range of 40-150 
nm. 
Consistent with observations from other groups 
in different models [36], we demonstrated that the 
protein composition of EVs is tumor supportive and 
more than 30% of proteins being anti-apoptotic and cell 
proliferative. As a proof of concept we have confirmed 
expression of 7 proteins; two proteins confirm the origin 
of the hMSCs EVs (CD90 and CD81) [37] and five 
known proteins associated with tumor proliferation and 
anti-metastasis [38-42]. Proteomics data supports the 
notion that the protein sorting in the EVs is not a random 
event: a) the constancy between the proteomic assays 
on EVs preparations from two different donors. b) The 
total number of proteins present in the preparation is less 
than 300, which are well within the range of number of 
proteins to be packaged into a less than 200 nm vesicle. 
This data further supports our conclusion that the EVs 
used in this study are homogenous population with limited 
contamination from commonly co-purified apoptotic blebs 
[43] and serum components that are rich in proteins. The 
variability of protein expression in EVs that are not seen 
in whole cell western could be explained by two possible 
scenarios: (a) a well regulated packaging of EVs with 
proteins that may not be highly expressed in cells (b) the 
western blot is normalized to the same amount of total 
protein, the data seen is function of ratio of specific protein 
to total number of proteins. 
Previous studies have suggested that lipid rafts 
may play a role in EV biogenesis and structure. The lipid 
metabolism studies in cancer has shown that alterations 
can affect the availability of structural lipids for the 
synthesis of membranes, the synthesis and degradation 
of lipids that contribute to energy homeostasis and the 
abundance of lipids with signaling functions. We tested 
the presence of bioactive lipids that are characteristic of 
EVs, the production of which is regulated by the ceramide 
pathway. HPLC/MS-MS lipid profiling demonstrated 
typical raft components were in hMSC-EVs. Relative 
abundance of diacyl-glycerol, sphingomyelin and 
ceramides further suggest the origins of the EVs through 
ceramide pathway as shown previously [44, 45 ]. The 
presence of sphingomyelins and diacylglyceraol data 
further supports the hypothesis that lipid raft composition 
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in EVs adds to the functional role of hMSC-EVs to 
support tumor growth. 
Similar to protein and nucleic acid, the metabolism 
is altered in tumors. Small molecule metabolites play a 
significant role in the breast tumor expansion. Warburg-
like metabolism is influenced by changes in stromal-
epithelial cell interactions, including metabolism 
related genes and epigenome [46]. Preliminary assays 
for metabolites has shown that EVs from hMSCs 
contain glutamic acid and lactic acid both of which are 
associated with tumor proliferation [47]. Glutamine is a 
known amino acid that traffics both carbon and nitrogen 
and provides precursors for basically all of the major 
macromolecular classes. The presence of lactic acid 
in the tumor microenvironment is associated with the 
increased ability of tumor cells to survive hypoxic and 
nutrient deprived core [48]. The low pH generated through 
lactic acid secretion through modified glucose/glutamine 
metabolism is attributed to cancers escape from immune 
surveillance. This data further supports our hypothesis that 
hMSCs provide an ideal tumor supportive environment, 
which includes lactic acid secretion.
To study the small nucleic acid components we 
performed deep sequencing assays and PCR array for 
known miRNA and lncRNA. A series of bioinformatics 
analysis revealed miRNA transported by EVs which 
are involved in functions like cell death, proliferation 
and survival. As a proof of concept, we performed over 
expression knock out assays for miRNAs- 21 and 34a, 
which supported our hypothesis [49]. Taken together, 
this genomic data provides a proof of concept that EVs 
from stressed hMSCs act as carriers that transport tumor 
supportive miRNA and lncRNA. MicroRNA- 21 is shown 
to stimulate proliferation in renal cell carcinoma and breast 
carcinoma [50, 51]. MicroRNA- 34a has been shown as a 
tumor supportive and inhibitory microRNA, putting it in 
the group of microRNA that exert contradictory functions 
[52, 53]. The anti-proliferative (or tumor suppressive) 
effect of miR- 34a is associated with its role in targeting 
transcription factor E2F3, however the cancers that have 
high expression of miR- 34a were shown to have low 
levels of E2F3 [52]. Taken together, our data demonstrates 
that miRNAs- 21 and 34a play a cell proliferative role 
in MCF-7 cells. As seen in vitro, pretreatment of EVs 
inhibited cell death when MCF-7 and KHOS cells 
were treated with serum free media. In addition, the in 
vivo assays verified that tumor supportive properties of 
hMSC- EVs. These results suggest that the transfer of 
small amounts of exogenous small RNA, proteins and 
lipids may aid in tumor progression. Functional assays to 
demonstrate that the EVs from hMSCs are breast tumor 
supportive corroborate our previous observations [9].
Metastatic breast cancers at stage 4 have a mortality 
rate of 85% in five years, while stage one is 15% [54]. 
Therefore, there is an urgent need to develop diagnostics 
for early identification of metastatic phenotype. While 
several groups are interested in studying the exosomes 
secreted by the tumor cells, this is the first comprehensive 
study to understand exosomes or EVs secreted by stromal 
cells. The integral role of stroma in tumor growth, 
dormancy and metastasis is well studied. In addition, the 
stromal components undergo changes in the solid tumor, 
understanding such changes would potentially provide 
a non-invasive diagnostic method for metastatic breast 
cancers. Our model mimics such changes that stromal 
cells would undergo with nutrient deprivation in a primary 
tumor. Therefore, further studies to explore the stromal 
EVs cargo would shed light on novel diagnostics for 
metastatic breast cancers.
In conclusion, this report offers a comprehensive 
analysis of extracellular vesicular cargo that sheds light on 
the cell communication in the tumor microenvironment. 
In this study, we show that EVs from stressed SD-MSCs 
act as rafts to carry tumor supportive proteins, miRNA, 
lipids and metabolites. Further studies are warranted to 
determine which of these components trigger the right 
molecular mechanisms in the tumor cells. 
MATERIALS AND METHODS
Cell culture
hMSCs from bone marrow aspirates were provided 
by the Texas A&M Health Science Center College of 
Medicine Institute for Regenerative Medicine at Scott & 
White through a grant from NCRR of the NIH, Grant # 
P40RR017447. The cells were obtained as frozen vials 
of passage 1 cells that were shown to be multipotent for 
differentiation. The cells were negative for hematopoietic 
markers (CD34, CD36, CD117, and CD45), and positive 
for CD29 (95%), CD44 (>93%), CD49c (99%), CD49f 
(>70%), CD59 (>99%), CD90 (>99%), CD105 (>99%) 
and CD166 (>99%). All cultures were cultured as 
described previously [9, 55]. MCF-7 and KHOS cell lines 
were obtained from ATCC and grown according to the 
recommended culture conditions. MCF-7 cells expressing 
GFP and luciferase used for in vivo experiments were 
generated previously [56]. 
Extracellular vesicles (EVs) isolation and 
characterization
EVs were isolated using a modified protocol 
described by Thery et al. [20]. Briefly, hMSCs were 
cultured in CCM until they were 80% confluent in two-
layered cell factories (Nunc) (30x106 cells). CCM was 
replaced with SDM and cells were grown under these 
serum-deprived conditions for a period up to 15 to 30 
days. Conditioned media of 250 ml was collected every 
3 days, centrifuged at 500 g for 10 min to eliminate cell 
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debris. The supernatant was concentrated using a positive 
pressure concentrator (Amicon 8400) with 1 kDa ultra-
filtration discs (Millipore) to a final volume of 5 ml and 
ultra-centrifuged at 15,000g for 1 h at 4oC to remove large 
vesicles, the supernatant which contain the EV fraction 
was further subjected to ultracentrifugation at 110,000 g 
for 18 h at 4oC. EV pellets were washed with PBS and 
ultracentrifuged at 110,000 g for 18 h at 4 oC and pellets 
were resuspended in 100 μl of PBS and aliquots were 
stored at -80oC. EVs, were characterized using NanoSight 
LM10 system (NanoSight Ltd, Amesbury, UK) and 
assayed with NTA software version 2.3 as described 
elsewhere [57]. 
Electron microscopy
Purified EVs were fixed in 4% paraformaldehyde 
(PFA) and deposited on Formvar carbon coated TEM grid 
in dry environment for 20 min. After EVs adsorption, grid 
was washed two times in PBS followed by three times 
in PBS/50 mM glycine for 3 min each. Then grid was 
transferred to a drop of blocking buffer (5% BSA in PBS) 
for 10 min. EVs were immunolabeled with mouse anti-
human CD-63 (Clone H5C6, BD Biosciences, San Jose, 
CA) and mouse anti-human CD-81 (Clone 1D6, Leica 
Microsystems, Buffalo Grove, IL) separately for 30 min. 
Antibody dilutions tested were 5 µg/ml as mentioned in the 
protocol by Thery et al. [20]. Control grids were incubated 
with mouse IgG1 (Clone MOPC-21, BD Biosciences, San 
Jose, CA). The grids were washed, treated with secondary 
antibody, stained with uranyl acetate and embedded in 
4% uranyl acetate and 2% methylcellulose as mentioned 
published [20]. The specimens were examined under 
acceleration voltage of 200 kV under a JEOL 2011 
transmission electron microscope.
EVs PKH26 labeling
EVs were labeled using the PKH26 red fluorescence 
cell linker kit (Sigma, St. Louis, MO) according to 
manufacturer’s instructions, EVs were washed four times 
with PBS. Labeled EVs were incubated with cells for 3 h 
on coverslips in a 24-well plate and viewed under Nikon 
Eclipse 80i fluorescence microscope and analyzed with 
NIS- elements BR software version 4.0.
Proteomics
Sample Preparation: To prepare mass spectrometry 
compatible peptides from EVs pelleted proteins, disulfide 
bonds were reduced with 20 mM dithiothreitol (DTT from 
Sigma-Aldrich, Lyon, France) for 30 min at 56°C, free 
thiols were then alkylated with 50 mM of chloroacetamide 
for 30 min at room temperature. The protein precipitate 
was resuspended in digestion buffer containing 50 mM 
ammonium bicarbonate (Sigma Aldrich, Lyon, France), 
1% RapiGest (Waters, En Yvelines Cedex, France) and 0.2 
μg of sequencing grade trypsin (Promega, Lyon, France) 
and digested 3 h at 37°C under frequent agitation. The 
reaction was stopped with 1 µL of 10% TFA (Fluka, Lyon, 
France). Resulting peptides were collected for subsequent 
analysis.
Nano Liquid Chromatography with Tandem Mass 
Spectrometry Analysis (LC-MS/MS):
Peptide concentration and separation was performed 
using a nanoflow liquid chromatographic system (Ultimate 
3000 RSLC from Dionex) coupled to a hybrid mass 
spectrometer (Linear Trap Quadrupole-Orbitrap Velos 
from Thermo Fisher Scientific) for peptide identification 
following manufacturer’s protocol. Trap CID MS/MS 
was performed on multi-protonated peptides in a data 
dependent scheme allowing up to 10 isolations and 
fragmentations between each high resolution full scan MS 
measurement of the continuous elution process. 
Protein Identification:
All LC-MS/MS results were analyzed using 
Proteome Discoverer 1.2 software (Thermo Fisher 
Scientific) in combination with Mascot MOWSE search 
algorithm [58] using the sequences contained in the 
January 2011 Swiss-prot FASTA database. Precursor 
mass tolerance was set to 2 ppm and fragment mass 
tolerance to 0.45 Da. Peptide false positive identification 
probability was <5%. All identified proteins from several 
injections were compared using the MyproMS data parser 
[59]. Proteins were confidently identified with at least 2 
different peptides with a score of identification ≥20.
Metabolomics
Lipids: EVs from two donors were isolated and 
multicomponent LC-MS/MS and/or SFC/MS/MS analysis 
was performed at Medical university of South Carolina 
lipidomics and pathobiology core. The EVs were tested for 
the presence of - Sphingoid bases (sphingosine, dihydro-
sphingosine), Sphingoid base-1- phosphates (S1P, dhS1P), 
ceramide (Cn-Cers), dihydro-ceramide, alpha-hydroxy-
ceramide, diacyl-glycerol (DAGs), sphingomyelin (SM), 
dihydro-SM, hexosylceramide (glucosyl- and galactosyl-
ceramide), lactosyl-ceramide and ceramide  1- phosphate 
molecular species, separated glucosyl and galactosyl–
ceramide species using methods (LC-MS/MS and/or SFC/
MS/MS) described in [60, 61].
Small molecule characterization
EVs sample was mixed with 200 µl methanol and 
sonicated for 30 sec. The lysate was analyzed by CE-UV 
and HPLC-MS/MS. CE conditions: column; 75 µm ID 
/370 µm OD x 50 cm long fused-silica capillary; sample 
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injection, pressure at 50 mbar for 10 sec; CE running 
buffer, 20 mM Tris-HCl buffer (pH 8.2); CE voltage, 
positive 25.0 kV; column temperature, 20oC. CE-UV 
analysis. An Agilent CE instrument (7100 Model) was 
used.
HPLC-MS analysis
The system consisted of a Surveyor HPLC and a 
TSQ triple quadrupole mass spectrometer equipped with 
a heated ESI source (Thermo Scientific, San Jose, CA, 
USA). Xcalibur software was used for data acquisition and 
process. A C18 reversed-phase column (Ascentis® 3 μm 
particle size, 10 cm × 2.1 mm, Sigma-Aldrich Chemicals, 
St, Louis, USA) was used for separation. MeOH/water 
mixture (50/50, v/v) containing 0.1% formic acid was used 
as the mobile phase at a flow rate of 0.200 ml/min. Sample 
injection volume was 5 µl. The MS detector was operated 
in the positive ion mode with the following settings: spray 
voltage 3 kV, vaporization temperature 270oC, capillary 
temperature 300°C, sheath gas pressure 35 (arb), auxiliary 
gas pressure 10 (arb), tube lens voltage of 150 V, and 
capillary voltage of 35V.
Genomics
Next generation sequencing: The small RNAs 
isolated from the EVs that are secreted from hMSCs 
were processed to generate a cDNA library, which was 
then used for deep sequencing. Sequencing of small 
RNAs from hMSCs EVs resulted in ≈16 million raw 
reads (Supplementary Figure S3A), out of which ≈13 
million were mappable reads. The mappable reads were 
grouped into several groups. Group 1a included miRNAs 
from human miRBase of specific species and this group 
was considered for further evaluation. First, miRNAs 
from group 1a were sorted based on the copy number, 
function and z score. A schematic for miRNA analysis is 
shown in Supplemental Figure S3B. Overall, the miRNAs 
from group 1a were divided into 6 groups based on their 
functions. Similarly long non-coding RNAs (lncRNAs) 
were sorted based on 8 mers sequence after eliminating 
duplicates and finally 4 lncRNAs were shortlisted 
(Supplemental Figure S3B). A miRNA microarray analysis 
was first performed on 585 known miRNAs sequences and 
we identified 134 miRNAs, which are negative regulators 
of apoptosis. Data crossover between the next generation 
sequencing and miRNA microarray confirmed that at 
least 10 miRNAs identified as involved in cell death, 
survival and proliferation of cells. For proof of concept, 
we selected miR-21 and miR-34a that are known to be 
involved in cell survival and proliferation.
Western blots
EVs secreted by SD-MSCs from two different 
human donors (days 36-40) were lysed in RIPA buffer 
(Santa Cruz, Dallas, TX) and protein contents estimated 
using microBCA assay (Pierce, Rockford, IL) and 
western blot assays were performed us 10 µg of proteins. 
Antibodies: PDGFR-β (Santa Cruz, cat# sc-432, 1:200), 
LAMP2 (Thermo Scientific, cat# MA1-20798, 1:200), 
TIMP-1 (Chemicon, cat#AB800, 1:1000), CD90 (BD 
Pharmingen, cat#555596, 1:200), TIMP-2 (Chemicon, 
cat#AB801, 1:1000), CD9 (AbCam cat#ab2215) and 
CD81 (AbCam cat#ab79559).  
Locked nucleic acid transfection
Cells were transfected with locked nucleic acids 
(LNAs) (Exiqon, Woburn, MA) using HappyFect reagent 
(Tecrea, London, UK) according to the manufacturers 
protocols. LNAs are used at a concentration of 10 pmol/
well, 20 pmol/well, and 50 pmol/well in 24, 12, and 
6-well plates, respectively. Sequences of miRCURY LNA 
inhibitors are:
hsa-miR-21 5’-3’ 
CAACATCAGTCTGATAAGCT/36-FAM; 
hsa-miR-34a 5’-3’ 
ACAACCAGCTAAGACACTGCC/36-FAM. 
Real Time RT-PCR analysis
For miRNA PCR arrays, total RNA was extracted 
from hMSCs or SD-MSCs using the RNeasy Mini Kit 
(Qiagen, Valencia, CA), and 500 ng of RNA was converted 
into cDNA with the RT2 First Strand Kit (SuperArray 
Bioscience, Frederick, MD). Real-time PCR was 
performed using the RT2 miRNA PCR array with the RT2 
SYBR Green Master Mix (both SuperArray Bioscience, 
Frederick, MD) according to the manufacturer’s protocol. 
PCR arrays were run with an ABI PRISM® 7900HT 
Sequence Detection System, (Applied Biosystems; Foster 
City CA) using the SDS 2.2 program. 
For miR-21 and 34a studies, total RNA was isolated 
from hMSCs, SD-MSCs and EVs using mirVana kit 
(Ambion, Grand Island, NY) according to manufacturer’s 
protocol. cDNA was established from 500 ng of total RNA 
using miScript II RT Kit (Qiagen, Valencia, CA), Real-
time PCR was performed with cDNA in triplicates using 
miScript SYBR Green PCR Kit (Qiagen, Valencia, CA) 
in CFX96 Real-Time PCR system (Bio-Rad, Hercules, 
CA). miRNA are amplified using the following primers, 
hsa-miR-21 5’-TAGCTTATCAGACTGATGTTGA-3’, 
hsa-miR-34a 5’-TGGCAGTGTCTTAGCTGGTTGT-3’, 
5sRNA 5’- TACGGCCATACCACCCTGAA-3’ and 
3’-GCGGTCTCCCATCCAAGTAC-5’. Anti-sense 
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primers were the universal primer set available in the kit. 
Qualitative analysis of cell survival using Celigo
Cells were transfected in 24 well plates in duplicates 
with LNAs using appropriate controls and analyzed for 
cell survival after 36 h using automatic cell analyzer 
Celigo (Cyntellect, San Diego, CA). Cells were fixed 
with 4% PFA for 10 min and after two washes stained 
with 0.5% v/v Hoechst 33342 (ImmunoChemistry 
Technologies, Bloomington, MN) for 10 min. After 
washing away the excess stain, the plate was scanned 
using Target 1 pre-program in Celigo. For analysis, cell 
area parameter was set at 120-10000 pixels to exclude cell 
debris and all the remaining parameters were default. Cell 
count was obtained based on the stained nuclei. Percentage 
cell survival was calculated after normalizing the values 
to respective negative controls from three individual 
experiments. 
Animal experiments
NU/NU female mice were purchased from Charles 
River Laboratories (Wilmington, MA). All animal studies 
were conducted in accordance with NIH animal use 
guidelines and a protocol approved by UMMC Animal 
Care Committee. Mice were 3 to 5 weeks and were 
randomly divided into 2 groups (n=8). MCF-7 gfp/luc 
cells were trypsinized and washed twice with PBS. Tumor 
volumes were calculated using the formula V= (4/3)πa2b, 
where a is shorter radius in mm and b is longer radius in 
mm.
Hematoxylin and Eosin staining
Breast tumors from different groups were excised 
from mice for H&E staining as described previously [62]. 
Statistical analysis
P values were calculated using Student’s two tailed 
t test. Differences were considered significant at P <0.05.
ACKNOWLEDGEMENTS
This work was supported in part by NIH Grant 
CA1515851 and the UMMC Cancer Institute startup funds 
to RP. 
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed by 
authors.
Author’s contribution
K.C.V. and P.P- Conception and design, 
development of methodology, acquisition of data, 
analysis and interpretation of data, writing and review of 
the manuscript; S.D., R.X., - Acquisition of data; F.G.-
acquisition of proteomics data; K.V.A, Y.L..-Analysis and 
interpretation of data; Y.Y.M.- material support; M.C.V., 
K.W.- material support, review of manuscript; R.P.-
Conception and design, analysis and interpretation of data, 
writing, review of manuscript, study supervision, financial 
support, final review of manuscript. 
REFERENCES
1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach 
I, Marini F, Krause D, Deans R, Keating A, Prockop D 
and Horwitz E. Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International Society for 
Cellular Therapy position statement. Cytotherapy. 2006; 
8(4):315-317.
2. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, 
Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg 
RA. Mesenchymal stem cells within tumour stroma promote 
breast cancer metastasis. Nature. 2007; 449(7162):557-563.
3. Roorda BD, Ter Elst A, Diks SH, Meeuwsen-de Boer TG, 
Kamps WA and de Bont ES. PTK787/ZK 222584 inhibits 
tumor growth promoting mesenchymal stem cells: kinase 
activity profiling as powerful tool in functional studies. 
Cancer Biol Ther. 2009; 8(13):1239-1248.
4. Stagg J. Mesenchymal stem cells in cancer. Stem Cell Rev. 
2008; 4(2):119-124.
5. Tsai KS, Yang SH, Lei YP, Tsai CC, Chen HW, Hsu CY, 
Chen LL, Wang HW, Miller SA, Chiou SH, Hung MC 
and Hung SC. Mesenchymal stem cells promote formation 
of colorectal tumors in mice. Gastroenterology. 2011; 
141(3):1046-1056.
6. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, 
Delaunay T, Naeem R, Carey VJ, Richardson AL and 
Weinberg RA. Stromal fibroblasts present in invasive 
human breast carcinomas promote tumor growth and 
angiogenesis through elevated SDF-1/CXCL12 secretion. 
Cell. 2005; 121(3):335-348.
7. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL 
and Hung SC. Mesenchymal stem cells promote growth 
and angiogenesis of tumors in mice. Oncogene. 2013; 
32(37):4343-4354.
8. Ljujic B, Milovanovic M, Volarevic V, Murray B, 
Bugarski D, Przyborski S, Arsenijevic N, Lukic ML and 
Stojkovic M. Human mesenchymal stem cells creating an 
immunosuppressive environment and promote breast cancer 
in mice. Sci Rep. 2013; 3:2298.
9. Sanchez CG, Penfornis P, Oskowitz AZ, Boonjindasup AG, 
Cai DZ, Dhule SS, Rowan BG, Kelekar A, Krause DS and 
Oncotarget4965www.impactjournals.com/oncotarget
Pochampally RR. Activation of autophagy in mesenchymal 
stem cells provides tumor stromal support. Carcinogenesis. 
2011; 32(7):964-972.
10. Pochampally RR, Smith JR, Ylostalo J and Prockop DJ. 
Serum deprivation of human marrow stromal cells (hMSCs) 
selects for a subpopulation of early progenitor cells with 
enhanced expression of OCT-4 and other embryonic genes. 
Blood. 2004; 103(5):1647-1652.
11. Caplan AI and Dennis JE. Mesenchymal stem cells as 
trophic mediators. Journal of cellular biochemistry. 2006; 
98(5):1076-1084.
12. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, 
Dvorak P and Ratajczak MZ. Embryonic stem cell-derived 
microvesicles reprogram hematopoietic progenitors: 
evidence for horizontal transfer of mRNA and protein 
delivery. Leukemia. 2006; 20(5):847-856.
13. Camussi G, Deregibus MC, Bruno S, Cantaluppi V and 
Biancone L. Exosomes/microvesicles as a mechanism of 
cell-to-cell communication. Kidney international. 2010; 
78(9):838-848.
14. Vallabhaneni K C PP, Griffin Orr J, Chauhan KM and 
Pochampally R. (2014). MicroRNA in Development and 
in the progression of Cancer. In: Rameshwar SRSaP, 
ed. Microvesicular transfer of microRNA in tumor 
microenvironment. (New York: Springer), pp. 327-348.
15. Yoshioka Y, Konishi Y, Kosaka N, Katsuda T, Kato T and 
Ochiya T. Comparative marker analysis of extracellular 
vesicles in different human cancer types. Journal of 
extracellular vesicles. 2013; 2.
16. Luga V and Wrana JL. Tumor-stroma interaction: Revealing 
fibroblast-secreted exosomes as potent regulators of Wnt-
planar cell polarity signaling in cancer metastasis. Cancer 
research. 2013; 73(23):6843-6847.
17. Wendler F, Bota-Rabassedas N and Franch-Marro X. 
Cancer becomes wasteful: emerging roles of exosomes in 
cell-fate determination. Journal of extracellular vesicles. 
2013; 2.
18. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and 
Lotvall JO. Exosome-mediated transfer of mRNAs and 
microRNAs is a novel mechanism of genetic exchange 
between cells. Nat Cell Biol. 2007; 9(6):654-659.
19. Choi DS, Kim DK, Kim YK and Gho YS. Proteomics, 
transcriptomics and lipidomics of exosomes and ectosomes. 
Proteomics. 2013; 13(10-11):1554-1571.
20. Thery C, Amigorena S, Raposo G and Clayton A. Isolation 
and characterization of exosomes from cell culture 
supernatants and biological fluids. Curr Protoc Cell Biol. 
2006; Chapter 3:Unit 3 22.
21. Ma Y, Bao-Han W, Lv X, Su Y, Zhao X, Yin Y, Zhang 
X, Zhou Z, MacNaughton WK and Wang H. MicroRNA-
34a mediates the autocrine signaling of PAR2-activating 
proteinase and its role in colonic cancer cell proliferation. 
PloS one. 2013; 8(8):e72383.
22. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, 
Krogh A and Lund AH. Programmed cell death 4 (PDCD4) 
is an important functional target of the microRNA miR-21 
in breast cancer cells. J Biol Chem. 2008; 283(2):1026-
1033.
23. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob 
ST and Patel T. MicroRNA-21 regulates expression of 
the PTEN tumor suppressor gene in human hepatocellular 
cancer. Gastroenterology. 2007; 133(2):647-658.
24. Kahlert C and Kalluri R. Exosomes in tumor 
microenvironment influence cancer progression and 
metastasis. J Mol Med (Berl). 2013; 91(4):431-437.
25. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom 
R, Oukrif D, Alison MR and Wright NA. Bone marrow 
contribution to tumor-associated myofibroblasts and 
fibroblasts. Cancer research. 2004; 64(23):8492-8495.
26. Hung SC, Pochampally RR, Hsu SC, Sanchez C, Chen SC, 
Spees J and Prockop DJ. Short-term exposure of multipotent 
stromal cells to low oxygen increases their expression of 
CX3CR1 and CXCR4 and their engraftment in vivo. PloS 
one. 2007; 2(5):e416.
27. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi 
S, Baik GH, Shibata W, Diprete B, Betz KS, Friedman R, 
Varro A, Tycko B and Wang TC. Bone marrow-derived 
myofibroblasts contribute to the mesenchymal stem cell 
niche and promote tumor growth. Cancer cell. 2011; 
19(2):257-272.
28. Shibata W, Ariyama H, Westphalen CB, Worthley DL, 
Muthupalani S, Asfaha S, Dubeykovskaya Z, Quante 
M, Fox JG and Wang TC. Stromal cell-derived factor-1 
overexpression induces gastric dysplasia through expansion 
of stromal myofibroblasts and epithelial progenitors. Gut. 
2013; 62(2):192-200.
29. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, 
Carey L, Richardson A and Weinberg RA. Reconstruction 
of functionally normal and malignant human breast tissues 
in mice. Proceedings of the National Academy of Sciences 
of the United States of America. 2004; 101(14):4966-4971.
30. Grum-Schwensen B, Klingelhofer J, Berg CH, El-
Naaman C, Grigorian M, Lukanidin E and Ambartsumian 
N. Suppression of tumor development and metastasis 
formation in mice lacking the S100A4(mts1) gene. Cancer 
research. 2005; 65(9):3772-3780.
31. Koukourakis MI, Giatromanolaki A, Harris AL and Sivridis 
E. Comparison of metabolic pathways between cancer cells 
and stromal cells in colorectal carcinomas: a metabolic 
survival role for tumor-associated stroma. Cancer research. 
2006; 66(2):632-637.
32. Yuan J and Glazer PM. Mutagenesis induced by the tumor 
microenvironment. Mutation research. 1998; 400(1-2):439-
446.
33. Pochampally R. Colony forming unit assays for MSCs. 
Methods Mol Biol. 2008; 449:83-91.
34. Sanchez C, Oskowitz A and Pochampally RR. Epigenetic 
reprogramming of IGF1 and leptin genes by serum 
Oncotarget4966www.impactjournals.com/oncotarget
deprivation in multipotential mesenchymal stromal cells. 
Stem Cells. 2009; 27(2):375-382.
35. Oskowitz A, McFerrin H, Gutschow M, Carter ML and 
Pochampally R. Serum-deprived human multipotent 
mesenchymal stromal cells (MSCs) are highly angiogenic. 
Stem Cell Res. 2011; 6(3):215-225.
36. Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson 
RJ, Hulett MD and Mathivanan S. Comparative proteomics 
evaluation of plasma exosome isolation techniques and 
assessment of the stability of exosomes in normal human 
blood plasma. Proteomics. 2013; 13(22):3354-3364.
37. Penfornis P, Cai DZ, Harris MR, Walker R, Licini D, 
Fernandes JD, Orr G, Koganti T, Hicks C, Induru S, 
Meyer MS, Khokha R, Barr J and Pochampally RR. High 
CD49f expression is associated with osteosarcoma tumor 
progression: a study using patient-derived primary cell 
cultures. Cancer Med. 2014.
38. Burduk PK, Bodnar M, Sawicki P, Szylberg L, Wisniewska 
E, Kazmierczak W, Martynska M and Marszalek A. 
Expression of metalloproteinases 2 and 9 and tissue 
inhibitors 1 and 2 as predictors of lymph node metastases in 
oropharyngeal squamous cell carcinoma. Head Neck. 2014.
39. Fernandez-Garcia B, Eiro N, Marin L, Gonzalez-
Reyes S, Gonzalez LO, Lamelas ML and Vizoso FJ. 
Expression and prognostic significance of fibronectin 
and matrix metalloproteases in breast cancer metastasis. 
Histopathology. 2014; 64(4):512-522.
40. Gustafson-Wagner E and Stipp CS. The CD9/CD81 
tetraspanin complex and tetraspanin CD151 regulate 
alpha3beta1 integrin-dependent tumor cell behaviors by 
overlapping but distinct mechanisms. PloS one. 2013; 
8(4):e61834.
41. Kwon HJ, Min SY, Park MJ, Lee C, Park JH, Chae JY 
and Moon KC. Expression of CD9 and CD82 in clear cell 
renal cell carcinoma and its clinical significance. Pathol Res 
Pract. 2014; 210(5):285-290.
42. Weissmueller S, Manchado E, Saborowski M, Morris 
JPt, Wagenblast E, Davis CA, Moon SH, Pfister NT, 
Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu 
J, Grimmond SM, Pilarsky C, Prives C, et al. Mutant 
p53 drives pancreatic cancer metastasis through cell-
autonomous PDGF receptor beta signaling. Cell. 2014; 
157(2):382-394.
43. Mathivanan S, Fahner CJ, Reid GE and Simpson RJ. 
ExoCarta 2012: database of exosomal proteins, RNA 
and lipids. Nucleic acids research. 2012; 40(Database 
issue):D1241-1244.
44. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, 
Wieland F, Schwille P, Brugger B and Simons M. Ceramide 
triggers budding of exosome vesicles into multivesicular 
endosomes. Science. 2008; 319(5867):1244-1247.
45. Phuyal S, Hessvik NP, Skotland T, Sandvig K and Llorente 
A. Regulation of exosome release by glycosphingolipids 
and flotillins. FEBS J. 2014; 281(9):2214-2227.
46. Brantley SD and Spies JB. Thoracodorsal artery aneurysm 
caused by fibromuscular dysplasia. AJR American journal 
of roentgenology. 1987; 149(5):1067-1068.
47. Marin-Valencia I, Cho SK, Rakheja D, Hatanpaa KJ, 
Kapur P, Mashimo T, Jindal A, Vemireddy V, Good LB, 
Raisanen J, Sun X, Mickey B, Choi C, Takahashi M, Togao 
O, Pascual JM, et al. Glucose metabolism via the pentose 
phosphate pathway, glycolysis and Krebs cycle in an 
orthotopic mouse model of human brain tumors. NMR in 
biomedicine. 2012; 25(10):1177-1186.
48. Sherman SL, Iselius L, Gallano P, Buckton K, Collyer S, 
DeMey R, Kristoffersson U, Lindsten J, Mikkelsen M, 
Morton NE and et al. Segregation analysis of balanced 
pericentric inversions in pedigree data. Clinical genetics. 
1986; 30(2):87-94.
49. Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S and 
Lee B. MicroRNA profiling identifies miR-34a and miR-21 
and their target genes JAG1 and WNT1 in the coordinate 
regulation of dendritic cell differentiation. Blood. 2009; 
114(2):404-414.
50. Fritz HK, Lindgren D, Ljungberg B, Axelson H and 
Dahlback B. The miR ratio as a prognostic marker in clear 
cell renal cell carcinoma. Eur J Cancer. 2014.
51. Terao M, Fratelli M, Kurosaki M, Zanetti A, Guarnaccia 
V, Paroni G, Tsykin A, Lupi M, Gianni M, Goodall GJ 
and Garattini E. Induction of miR-21 by retinoic acid in 
estrogen receptor-positive breast carcinoma cells: biological 
correlates and molecular targets. J Biol Chem. 2011; 
286(5):4027-4042.
52. Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, 
Hu Q, Yoshihara M, Ohara H, Takehashi M, Shinohara 
T, Masutani H, Onuki J and Toyokuni S. Association of 
microRNA-34a overexpression with proliferation is cell 
type-dependent. Cancer Sci. 2007; 98(12):1845-1852.
53. Fabian MR, Sonenberg N and Filipowicz W. Regulation of 
mRNA translation and stability by microRNAs. Annu Rev 
Biochem. 2010; 79:351-379.
54. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner 
LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD and 
Sparano JA. Survival in patients with metastatic recurrent 
breast cancer after adjuvant chemotherapy: little evidence 
of improvement over the past 30 years. Cancer. 2013; 
119(6):1140-1148.
55. Penfornis P and Pochampally R. Isolation and expansion of 
mesenchymal stem cells/multipotential stromal cells from 
human bone marrow. Methods Mol Biol. 2011; 698:11-21.
56. Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, Pai 
SK, Mo YY, Iiizumi-Gairani M, Hirota S, Liu Y, Wu K, 
Pochampally R and Watabe K. miR-7 suppresses brain 
metastasis of breast cancer stem-like cells by modulating 
KLF4. Cancer research. 2013; 73(4):1434-1444.
57. Webber J and Clayton A. How pure are your vesicles? 
Journal of extracellular vesicles. 2013; 2.
58. Perkins DN, Pappin DJ, Creasy DM and Cottrell JS. 
Oncotarget4967www.impactjournals.com/oncotarget
Probability-based protein identification by searching 
sequence databases using mass spectrometry data. 
Electrophoresis. 1999; 20(18):3551-3567.
59. Poullet P, Carpentier S and Barillot E. myProMS, a web 
server for management and validation of mass spectrometry-
based proteomic data. Proteomics. 2007; 7(15):2553-2556.
60. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM and 
Bielawska A. Sphingolipid analysis by high performance 
liquid chromatography-tandem mass spectrometry (HPLC-
MS/MS). Adv Exp Med Biol. 2010; 688:46-59.
61. Sullards MC, Liu Y, Chen Y and Merrill AH, Jr. Analysis 
of mammalian sphingolipids by liquid chromatography 
tandem mass spectrometry (LC-MS/MS) and tissue imaging 
mass spectrometry (TIMS). Biochim Biophys Acta. 2011; 
1811(11):838-853.
62. Marsden CG, Wright MJ, Carrier L, Moroz K, Pochampally 
R and Rowan BG. “A novel in vivo model for the study of 
human breast cancer metastasis using primary breast tumor-
initiating cells from patient biopsies”. BMC Cancer. 2012; 
12:10.
